Collaboration between Colentina Clinical Hospital and the transplant centers: A chance for life
Authors:   Hematology Department, Colentina Clinical Hospital, Bucharest, Romania, GEORGESCU Georgeta Daniela , MIHAI Felicia ,   Hematology Department, Colentina Clinical Hospital, Bucharest, Romania, OMER Meilin ,   Hematology Department, Colentina Clinical Hospital, Bucharest, Romania, POPOV Viola ,   Hematology Department, Colentina Clinical Hospital, Bucharest, Romania, ANDREESCU Mihaela ,   Hematology Department, Colentina Clinical Hospital, Bucharest, Romania, POPESCU Mihaela ,   Hematology Department, Colentina Clinical Hospital, Bucharest, Romania, PATRINOIU Oana ,   Hematology Department, Colentina Clinical Hospital, Bucharest, Romania, OFITERU Geanina ,   Hematology Department, Colentina Clinical Hospital, Bucharest, Romania, BALEA Marius ,   Hematology Department, Colentina Clinical Hospital, Bucharest, Romania, ION Silvia ,   Hematology Department, Colentina Clinical Hospital, Bucharest, Romania, CIORTAN Silvia ,   Hematology Department, Colentina Clinical Hospital, Bucharest, Romania, DESPAN Claudia ,   Hematology Department, Colentina Clinical Hospital, Bucharest, Romania
Published: August 2021

Background. Stem cell transplantation is an important therapeutic approach for patients with malignant hemopathies, whether we refer to autologous or allogeneic stem cell transplantation. Aims and methods. We present the characteristics of a group of 54 patients diagnosed with malignant haemopathy in the Department of Hematology of the Colentina Clinical Hospital, between 2004 and 2018, and who have benefited from stem cell transplantation both in the country and abroad. The data analyzed were: diagnosis of the disease, type of response to induction therapy, type and timing of transplantation, transplant in first remission or relapse, if there were patients who benefited from a second transplant, post-transplant survival, as well as demographics. The statistical analysis was performed using the system MedCalc Statistical Software Version 18.11.3. Results and conclusions. Survival analysis was applied separately for autotransplant patients and those who benefited from allotransplant (Kaplan Meier survival analyses). Significant differences were observed due to transplantation type and due to relapse after transplant, in our lot of patients. Post-transplant recurrence was an unfavorable prognostic factor for both autologous and allogeneic transplanted patients. Update. A new challenge: The COVID-19 pandemic threat. The SARS-CoV-2 infection is a threat for immunocompromised patients. From a group of 9 patients hospitalized in 2020 for COVID-19 in the Department of Hematology of the Colentina Clinical Hospital, and who have benefited in the past from stem cell transplantation (2 patients) or organ transplant (1 patient – lung, 3 patients – liver, 3 patients – kidney) in Romania, 4 of them have required hospitalization in the Intensive Care Unit (ICU) (authors's observational data). New data are needed to elucidate the prognostic factors to establish the outcome of transplant patients such as for all cancer patients or immunocompromised patients in the current COVID pandemic 19 era and the impact on public health.